There is a risk of serotonin syndrome when combining Lithium with MXE, as Lithium can induce serotonin syndrome in conjunction with other serotonergic drugs, and MXE has shown a notable affinity for the serotonin transporter.
Lenox, R. H., & Hahn, C. G. (2000). Overview of the mechanism of action of lithium in the brain: fifty-year update. The Journal of clinical psychiatry, 61 Suppl 9, 5–15. - https://pubmed.ncbi.nlm.nih.gov/10826655/
Shahani, L. (2012). Venlafaxine Augmentation With Lithium Leading to Serotonin Syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences, 24(3), E47–E47. https://doi.org/10.1176/appi.neuropsych.11080196
DeBattista, C., Sofuoglu, M., & Schatzberg, A. F. (1998). Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. Biological psychiatry, 44(5), 341–347. https://doi.org/10.1016/s0006-3223(98)00161-9
Massot, O. (1999). 5-HT1B Receptors: A Novel Target for Lithium Possible Involvement in Mood Disorders. Neuropsychopharmacology, 21(4), 530–541. https://doi.org/10.1016/S0893-133X(99)00042-1
Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X.-P., Setola, V., Treble, R., & Iversen, L. (2013). The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor. PLoS ONE, 8(3), e59334. https://doi.org/10.1371/journal.pone.0059334
Marti, M., Talani, G., Miliano, C., Bilel, S., Biggio, F., Bratzu, J., Diana, M., De Luca, M. A., & Fattore, L. (2021). New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat. Experimental Neurology, 345, 113836. https://doi.org/10.1016/j.expneurol.2021.113836
AlanaRm-rf-me
commented
1 month ago
Lithium + MXE = Dangerous
There is a risk of serotonin syndrome when combining Lithium with MXE, as Lithium can induce serotonin syndrome in conjunction with other serotonergic drugs, and MXE has shown a notable affinity for the serotonin transporter.
Lenox, R. H., & Hahn, C. G. (2000). Overview of the mechanism of action of lithium in the brain: fifty-year update. The Journal of clinical psychiatry, 61 Suppl 9, 5–15. - https://pubmed.ncbi.nlm.nih.gov/10826655/
Shahani, L. (2012). Venlafaxine Augmentation With Lithium Leading to Serotonin Syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences, 24(3), E47–E47. https://doi.org/10.1176/appi.neuropsych.11080196
DeBattista, C., Sofuoglu, M., & Schatzberg, A. F. (1998). Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. Biological psychiatry, 44(5), 341–347. https://doi.org/10.1016/s0006-3223(98)00161-9
Massot, O. (1999). 5-HT1B Receptors: A Novel Target for Lithium Possible Involvement in Mood Disorders. Neuropsychopharmacology, 21(4), 530–541. https://doi.org/10.1016/S0893-133X(99)00042-1
Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X.-P., Setola, V., Treble, R., & Iversen, L. (2013). The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor. PLoS ONE, 8(3), e59334. https://doi.org/10.1371/journal.pone.0059334
Marti, M., Talani, G., Miliano, C., Bilel, S., Biggio, F., Bratzu, J., Diana, M., De Luca, M. A., & Fattore, L. (2021). New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat. Experimental Neurology, 345, 113836. https://doi.org/10.1016/j.expneurol.2021.113836